Rotavirus vaccine developed in India demonstrates strong efficacy

Public-private partnership announces phase III clinical trial results at conference in Delhi

2013-05-14

(Press-News.org) New Delhi, India—The Government of India's Department of Biotechnology (DBT) and Bharat Biotech announced positive results from a Phase III clinical trial of a rotavirus vaccine developed and manufactured in India. Data from the trial, presented today at the International Symposium on Rotavirus Vaccines for India—The Evidence and the Promise, showed ROTAVAC® to have an excellent safety and efficacy profile.

The clinical study demonstrates for the first time that the India-developed rotavirus vaccine ROTAVAC® is efficacious in preventing severe rotavirus diarrhoea in low-resource settings in India. ROTAVAC® significantly reduced severe rotavirus diarrhoea by more than half—56 percent during the first year of life, with protection continuing into the second year of life. Moreover, the vaccine also showed impact against severe diarrhoea of any cause.

"This is an important scientific breakthrough against rotavirus infections, the most severe and lethal cause of childhood diarrhoea, responsible for approximately 100,000 deaths of small children in India each year," said DBT Secretary Dr K. VijayRaghavan. "The clinical results indicate that the vaccine, if licensed, could save the lives of thousands of children each year in India."

The vaccine was developed through a unique social innovation partnership that brought together the experience and expertise of Indian and international researchers as well as the public and private sectors. The vaccine originated from an attenuated (weakened) strain of rotavirus that was isolated from an Indian child at the All India Institute of Medical Sciences in New Delhi in 1985-86. Since then, partners have included DBT, Bharat Biotech, the US National Institutes of Health (NIH), the US Centers for Disease Control and Prevention (CDC), Stanford University School of Medicine, and the nongovernmental organization, PATH. Dr M.K. Bhan, who recently completed his service as DBT Secretary, was tireless in fostering the social innovation partnership and ensuring the highest standards for the vaccine.

The randomized, double-blind, placebo-controlled Phase III clinical trial enrolled 6,799 infants in India (aged six to seven weeks at the time of enrolment) at three sites—the Centre for Health Research and Development, Society for Applied Studies (SAS) in New Delhi; Shirdi Sai Baba Rural Hospital, KEM Hospital Research Centre in Vadu, Pune; and Christian Medical College (CMC) in Vellore. The Clinical Operations Management Unit headed by Dr Nita Bhandari at SAS oversaw the day-to-day coordination and logistical complexities of this multi-site study and played a pivotal role in the conduct of this trial. The Principal Investigators were Dr Temsunaro Rongsen-Chandola at SAS, Dr Ashish Bavdekar at KEM, and Dr Gagandeep Kang at CMC.

The Data Safety Monitoring Board (DSMB), an independent group of experts established to protect the participating infants' rights and needs during the Phase III trial, determined that the trial met the highest standards for ethics and patient care and complied with international standards for good clinical practices.

Bharat Biotech previously announced a price of US$ 1.00/dose (or approximately INR 54/dose) for ROTAVAC® and will soon file for registration of the vaccine in India. If licensed by the Drugs Controller General of India (DCGI), the vaccine will be a more affordable alternative to the rotavirus vaccines already on the market.

"With its low price and strong efficacy, ROTAVAC® has the potential to significantly reduce the incidence of severe diarrhoea due to rotavirus among children in India," said Dr M.K. Bhan, Advisor to the Indian Academy of Pediatrics and former DBT Secretary.

The vaccine efficacy compares favourably with the efficacy of the currently licensed rotavirus vaccines in low-resource countries. The study results showed clear evidence of protection across different rotavirus strains and continued efficacy in the second year of life.

Infants enrolled in the study received ROTAVAC® and the Universal Immunization Programme (UIP) vaccines, including oral polio vaccine (OPV). When the immune responses to OPV were tested, the result showed that infants receiving OPV at the same time as ROTAVAC® generated comparable immune responses to all three polio serotypes as the infants receiving OPV without ROTAVAC®; this result supports the concurrent administration of OPV and ROTAVAC®.

"Vaccines work to save and protect children from diseases like rotavirus for a lifetime," said Bill Gates, Co-Chair of the Bill & Melinda Gates Foundation. "This public-private partnership is an exemplary model of how to develop affordable technologies that save lives."

The vaccine development partnership was supported by DBT, the Bill & Melinda Gates Foundation, the Research Council of Norway, and the UK Department for International Development. Bharat Biotech invested important technical, manufacturing, and financial resources towards vaccine development. ROTAVAC® is an oral vaccine and is administered to infants in a three-dose course at the ages of 6, 10, and 14 weeks. It is given alongside routine immunizations in the UIP vaccines recommended at these ages.

"ROTAVAC® represents the successful research and development of a novel vaccine from the developing world with global standards," said Dr Krishna M. Ella, Chairman and Managing Director of Bharat Biotech. "ROTAVAC® is a testament of our strong vision and commitment to develop affordable health care solutions for infectious diseases—we are proud, yet humbled by our contribution to this social innovation project and global public health priority. We are thankful to all the partners in the Rotavirus Vaccine Development Project—DBT, the Indian Council of Medical Research, PATH, the Bill & Melinda Gates Foundation, NIH , CDC, and Stanford University—for their valuable support in this unique international public-private partnership."

Prior to conducting the study, the investigators received approvals from the DCGI, the Institutional Review Board for DBT, and the ethics review committees of each study site. The study partners also consulted with the State Governments of Delhi, Maharashtra, and Tamil Nadu, as well as the Ministry of Health and Family Welfare. In addition, the study was approved by the Western Institutional Review Board in the United States and met the highest international clinical trial standards. The DSMB strictly monitored the trial throughout for adherence to these standards and protocols. The trial design included a strong safety net to identify and treat illnesses, especially gastroenteritis, among study infants as early as possible. All of the infants enrolled in the trial received high-quality medical and emergency care during the trial period.

The support laboratory was the Translational Health Science and Technology Institute with Dr Sudhanshu Vrati as the lead. Quintiles was responsible for several aspects of the trial including medical monitoring, data management, site monitoring, pharmacovigilance, and biostatistics. Good Clinical Practice compliance of the clinical trials was audited by ANTHA Clinical Quality Assurance.

### Additional resources for media: Description of the social innovation partnership that developed ROTAVAC® Fact sheet on rotavirus disease burden in India Fact sheet on efficacy and impact of rotavirus vaccines Additional quotes and media statements from experts

This document is available online in English, Hindi, Tamil, Telegu, and Marathi: http://www.defeatdd.org/rotavac-clinical-trial-results

DBT website: http://dbtindia.nic.in Bharat Biotech website: http://www.bharatbiotech.com

Media contacts:

For DBT: Dr T.S. Rao, +91 98-7348-3538, tsrao@dbt.nic.in

For Bharat Biotech: Sheela Panicker, EnRight PR, +91 98-4980-9594, Sheela@enrightpr.com Muralidharan, EnRight PR, +91 98-8510-9594, Murali@enrightpr.com

For PATH (and to reach US NIH and CDC experts): Sushmita Malaviya, +91 97-1724-3131, smalaviya@path.org

Global media can contact: Guillermo Meneses, GMMB, +1-202-445-1570, Guillermo.Meneses@gmmb.com Allison Clifford, PATH, +1-202-669-7238, aclifford@path.org END

ELSE PRESS RELEASES FROM THIS DATE:

Cognitive training improves executive function in breast cancer survivors

2013-05-14

Women whose breast cancer had been treated with chemotherapy demonstrated improved executive function, such as cognitive flexibility, verbal fluency and processing speed after using exercises developed by Lumosity, the leading online cognitive training program. The study also found significant improvement in self-reported measures of everyday executive function and observed some transfer to verbal memory. Researchers at Stanford University published the results in the peer-reviewed journal, Clinical Breast Cancer. Dr. Shelli Kesler, Assistant Professor of Psychiatry and ...

Flower power fights orchard pests

2013-05-14

WENATCHEE, Wash. – Washington State University researchers have found they can control one of fruit growers' more severe pests, aphids, with a remarkably benign tool: flowers. The discovery is a boon for organic as well as conventional tree fruit growers. The researchers recently published their study in the journal Biological Control. They found that plantings of sweet alyssum attracted a host of spiders and predator bugs that in turn preyed on woolly apple aphids, a pest that growers often control with chemical sprays. "The results were striking," said Lessando Gontijo, ...

Playing at pirate games

2013-05-14

The results of a large-scale, analysis of BitTorrent file-sharing of computer games, focusing on using open methodologies are to be published in the International Journal of Advanced Media and Communication and bust some of the common myths about digital piracy. The controversy about illegal file sharing over the Internet has been a focus of intense attention from industry and media alike for the past decade. Despite the massive financial interests involved, there is, however, only limited factual knowledge available backing claims from either side of the controversy. Focusing ...

Do potatoes grow on vines? A review of the wild relatives of some favorite food plants

2013-05-14

The Solanaceae, also called the potato or nightshade family, includes a wide range of flowering plants, some of which are important agricultural crops. Tomatoes, potatoes, aubergines, peppers and wolfberries are all representatives of the family present on many tables across the world. Solanum is the largest genus of the family, and with 1500 species, is one of the largest genera of flowering plants. Solanum has 13 major evolutionary groups,or clades. This new study published in the open access journal Phytokeys offers a complete revision of all of the species of the Dulcamaroid ...

IT industry ignores silver surfers at its peril

2013-05-14

Hardware and software vendors are foolish to ignore the needs of the growing population of older computer and information technology users, the so-called "silver surfers". US researchers offer convincing evidence in a monograph to be published in the International Journal of Intercultural Information Management that from the business perspective, seniors represent a rapidly growing sector of the market with the most disposable income to spend on these companies' products. Mark McMurtrey, Ronald McGaughey, James Downey and Steven Zeltmann of the Department of Management ...

Fish oil may stall effects of junk food on brain

2013-05-14

Data from more than 180 research papers suggests fish oils could minimise the effects that junk food can have on the brain, a review by researchers at the University of Liverpool has shown. The team at the University's Institute of Ageing and Chronic Disease reviewed research from around the world to see whether there was sufficient data available to suggest that omega-3s had a role to play in aiding weight loss. Research over the past 10 years has indicated that high-fat diets could disrupt neurogenesis, a process that generates new nerve cells, but diets rich in omega-3s ...

Sulfate aerosols cool climate less than assumed

2013-05-14

This news release is available in German. In their role as condensation nuclei, aerosol particles are an important trigger for the formation of clouds. As humidity accumulates on the particles droplets are formed, which later develop into clouds. Within the clouds, however, the chemical composition of these aerosol particles changes. In order to find out exactly what happens within the clouds, Eliza Harris and Bärbel Sinha from the Max Planck Institute for Chemistry, together with other scientists form Mainz and further research institutes, investigated different ...

But what does it do?

2013-05-14

Although we know the tool's general purpose, it can sometimes be difficult to tell if a specific pair of precision tweezers belongs to a surgeon or a master jeweller. It is now easier to solve similar conundrums about a type of protein that allows cells to react to their environment, thanks to scientists at the European Molecular Biology Laboratory (EMBL). Published today in Science Signaling, their work offers a valuable resource for other researchers. Whether in your eye being hit by light, in your blood fighting off disease, or elsewhere throughout your body, cells ...

Cooling ocean temperature could buy more time for coral reefs

2013-05-14

Limiting the amount of warming experienced by the world's oceans in the future could buy some time for tropical coral reefs, say researchers from the University of Bristol. The study, published by the journal Geophysical Research Letters, used computer models to investigate how shallow-water tropical coral reef habitats may respond to climate change over the coming decades. Elena Couce and colleagues found that restricting greenhouse warming to three watts per square metre (equivalent to just 50-100 parts per million carbon dioxide, or approximately half again the increase ...

New software spots, isolates cyber-attacks to protect networked control systems

2013-05-14

Researchers from North Carolina State University have developed a software algorithm that detects and isolates cyber-attacks on networked control systems – which are used to coordinate transportation, power and other infrastructure across the United States. Networked control systems are essentially pathways that connect and coordinate activities between computers and physical devices. For example, the systems that connect temperature sensors, heating systems and user controls in modern buildings are networked control systems. But, on a much larger scale, these systems ...

LAST 30 PRESS RELEASES:

Mathematical model illuminates how environment impacts life choices of salmon

Houston Methodist researchers shed light on increased rates of severe human infections caused by Streptococcus subspecies

Change of ownership in home health agencies may lead to increased Medicare spending and reduced staffing levels, according to UTHealth Houston research